Related Experiment Videos

Mutational effects on the p16INK4a tumor suppressor protein

R Yang1, A F Gombart, M Serrano

  • 1Division of Hematology/Oncology, University of California, Los Angeles 90048, USA.

Cancer Research
|June 15, 1995
PubMed

Insights

Investigating p16INK4a mutations reveals that alterations in conserved ankyrin regions impact protein activity. However, not all tumor-associated mutations affect p16INK4a function, and the COOH-terminal region is dispensable for CDK4 inhibition.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Protein Biochemistry

Background:

  • The p16INK4a protein is a key cell cycle regulator frequently altered in various cancers.
  • Understanding the functional impact of p16INK4a mutations is crucial for cancer therapy development.
  • The ankyrin repeat domain is critical for the structure and function of proteins like p16INK4a and p15INK4b.

Purpose of the Study:

  • To functionally characterize point mutations and deletional mutants of p16INK4a.
  • To determine the effect of specific mutations on p16INK4a's ability to bind and inhibit CDK4.
  • To elucidate the role of ankyrin repeats in p16INK4a's activity and its relationship with p15INK4b.

Main Methods:

  • Site-specific mutagenesis was employed to create point mutants of p16INK4a.
  • Deletional mutants of p16INK4a were generated to assess domain importance.
  • Functional activity was assessed using the yeast two-hybrid system and in vitro kinase assays.

Main Results:

  • Point mutations within the conserved ankyrin consensus sequences altered p16INK4a activity.
  • Not all p16INK4a mutations found in tumors demonstrated a detectable impact on protein function.
  • The COOH-terminal region of p16INK4a was not essential for CDK4 binding or inhibition.
  • Deletion of the fourth ankyrin repeat completely abolished p16INK4a's inhibitory activity.

Conclusions:

  • The ankyrin repeat domain is critical for p16INK4a's tumor suppressor function.
  • Specific mutations in p16INK4a can impair its cell cycle regulatory activity, contributing to oncogenesis.
  • Further research into p16INK4a mutations may reveal novel therapeutic targets in cancer treatment.

Related Concept Videos